<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01413022</url>
  </required_header>
  <id_info>
    <org_study_id>201201124</org_study_id>
    <secondary_id>NCI-2011-01154</secondary_id>
    <nct_id>NCT01413022</nct_id>
  </id_info>
  <brief_title>FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma</brief_title>
  <official_title>Phase IB Study of FOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and optimal dose of PF-04136309 when given with&#xD;
      combination chemotherapy (FOLFIRINOX; 5-fluorouracil, leucovorin, irinotecan, oxaliplatin) in&#xD;
      treating patients with locally advanced or borderline resectable pancreatic cancer. These&#xD;
      patients are not candidates for surgical resection which is the most effective treatment for&#xD;
      pancreatic cancer. Giving PF-04136309 together with FOLFIRINOX may shrink pancreatic tumors&#xD;
      in some patients so that surgery becomes an option&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      To define the optimal dose and toxicity of PF-04136309 in combination with FOLFIRINOX&#xD;
      (fluorouracil, leucovorin calcium, irinotecan hydrochloride, and oxaliplatin) in patients&#xD;
      with borderline resectable and locally advanced pancreatic cancer.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
        -  To evaluate the safety of PF-04136309 and FOLFIRINOX by grade 3 or 4 toxicity for&#xD;
           clinical use.&#xD;
&#xD;
        -  To determine the tumor control rate (TCR) as defined by stable disease (SD), partial&#xD;
           response (PR), and complete response (CR): TCR = SD + PR + CR.&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
        -  To determine the prevalence and function of myeloid-derived suppressor cells (MDSC) in&#xD;
           the bone marrow, peripheral circulation, and tumor before and after treatment with&#xD;
           PF-04136309 and FOLFIRINOX.&#xD;
&#xD;
        -  To determine the prevalence and function of MDSC in the bone marrow, peripheral&#xD;
           circulation, and tumor before and after treatment with FOLFIRINOX.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal dose and dose-limiting toxicity of PF-04136309 in combination with FOLFIRINOX</measure>
    <time_frame>28 days</time_frame>
    <description>After completion of two cycles. To find the optimal dose, a 3+3 design will be used.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of PF-04136309 and FOLFIRINOX by grade 3 or 4 toxicity for clinical use.</measure>
    <time_frame>120 days (30 days after completion of treatment)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response rate: TCR = SD + PR + CR</measure>
    <time_frame>90 days (completion of cycle 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and function of MDSC in the bone marrow and tumor before and after treatment with PF-04136309 plus FOLFIRINOX or with FOLFIRINOX alone</measure>
    <time_frame>Baseline and end of cycle 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence and function of MDSC in peripheral circulation before and after treatment with PF-04136309 plus FOLFIRINOX or with FOLFIRINOX alone</measure>
    <time_frame>Baseline, before cycle 2, before cycle 4, and before cycle 6</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Pancreatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive FOLFIRINOX chemotherapy comprising of:&#xD;
oxaliplatin 85 mg/m2 IV on Day 1&#xD;
irinotecan 180 mg/m2 IV on Day 1&#xD;
leucovorin 400 mg/m2 IV on Day 1&#xD;
5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1&#xD;
Treatment is repeated every 14 days for 6 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive FOLFIRINOX chemotherapy comprising of:&#xD;
oxaliplatin 85 mg/m2 IV on Day 1&#xD;
irinotecan 180 mg/m2 IV on Day 1&#xD;
leucovorin 400 mg/m2 IV on Day 1&#xD;
5FU 400 mg/m2 bolus and 2400 mg/m2 CIVI over 46 hours beginning on Day 1&#xD;
PF-04136309 500 mg PO BID on days 1-14&#xD;
Treatment is repeated every 14 days for 6 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <other_name>1-OHP</other_name>
    <other_name>Dacotin</other_name>
    <other_name>Dacplat</other_name>
    <other_name>Eloxatin</other_name>
    <other_name>L-OHP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <other_name>Campto</other_name>
    <other_name>Camptosar</other_name>
    <other_name>CPT-11</other_name>
    <other_name>U-101440E</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <other_name>CF</other_name>
    <other_name>CFR</other_name>
    <other_name>LV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <other_name>5-fluorouracil</other_name>
    <other_name>5-Fluracil</other_name>
    <other_name>5-FU</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group A (FOLFIRINOX chemotherapy)</arm_group_label>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-04136309</intervention_name>
    <arm_group_label>Group B (FOLFIRINOX and PF-04136309)</arm_group_label>
    <other_name>PF-4136309</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient must have histologically or cytologically confirmed pancreatic adenocarcinoma&#xD;
             which is borderline resectable or locally advanced; tumors considered borderline&#xD;
             include the following: (a) no distant metastases; (b) venous involvement of the&#xD;
             superior mesenteric vein/portal vein demonstrating tumor abutment with or without&#xD;
             impingement and narrowing of the lumen, encasement of the superior mesenteric&#xD;
             vein/portal vein but without encasement of the nearby arteries, or short segment&#xD;
             venous occlusion resulting from either tumor thrombus or encasement but with suitable&#xD;
             vessel proximal and distal to the area of vessel involvement, allowing for safe&#xD;
             resection and reconstruction; (c) gastroduodenal artery encasement up to the hepatic&#xD;
             artery with either short segment encasement or direct abutment of the hepatic artery,&#xD;
             without extension to the celiac axis; (d) tumor abutment of the superior mesenteric&#xD;
             artery not to exceed 180 degrees of the circumference of the vessel wall&#xD;
&#xD;
          -  Patient must have radiographically measurable disease defined as lesions that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded) as &gt;=&#xD;
             10 mm with computed tomography (CT) scan or magnetic resonance imaging (MRI) or &gt;= 10&#xD;
             mm with calipers by clinical exam&#xD;
&#xD;
          -  Patient myst be &gt;= 18 years of age.&#xD;
&#xD;
          -  Patient must have life expectancy of &gt; 6 months&#xD;
&#xD;
          -  Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 1&#xD;
&#xD;
          -  Patient must have normal bone marrow and organ function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;= 1,500/mcl&#xD;
&#xD;
               -  Platelets &gt;= 100,000/mcl&#xD;
&#xD;
               -  Hemoglobin &gt;= 9.0 g/dL&#xD;
&#xD;
               -  Creatinine should be below the upper limit of normal OR creatinine clearance &gt;=&#xD;
                  60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal&#xD;
                  limits&#xD;
&#xD;
          -  Patient not on anticoagulation must have International Normalized Ratio (INR) and&#xD;
             activated partial thromboplastin time (PTT) &lt; 1.5 x ULN&#xD;
&#xD;
          -  Patients who have had a stent placed for biliary obstruction can be included in the&#xD;
             study&#xD;
&#xD;
          -  Women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control, abstinence) prior to study entry and for&#xD;
             the duration of study participation; should a woman become pregnant or suspect she is&#xD;
             pregnant while participating in this study, she must inform her treating physician&#xD;
             immediately&#xD;
&#xD;
          -  Patient must be able to understand and willing to sign an institutional review board&#xD;
             (IRB) approved written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient must not have evidence of neuroendocrine tumor, duodenal adenocarcinoma, or&#xD;
             ampullary adenocarcinoma&#xD;
&#xD;
          -  Patient must not have a history of other malignancy =&lt; 3 years previous with the&#xD;
             exception of basal cell or squamous cell carcinoma of the skin which were treated with&#xD;
             local resection only or carcinoma in situ of the cervix&#xD;
&#xD;
          -  Patient must not have received any chemotherapy or radiation for pancreatic cancer&#xD;
&#xD;
          -  Patient must not be receiving any other investigational agents&#xD;
&#xD;
          -  Patient must not have brain metastases; such patients must be excluded from this&#xD;
             clinical trial because of their poor prognosis and because they often develop&#xD;
             progressive neurologic dysfunction that would confound the evaluation of neurologic&#xD;
             and other adverse events&#xD;
&#xD;
          -  Patient must not have a history of allergic reactions attributed to compounds of&#xD;
             similar chemical or biologic composition to PF-04136309, 5FU (fluorouracil),&#xD;
             oxaliplatin, or irinotecan&#xD;
&#xD;
          -  Patient must not be on any CYP3A4 inhibitors or inducers as they may have interaction&#xD;
             with PF-04136309 and/or irinotecan&#xD;
&#xD;
          -  Patient must not have an uncontrolled intercurrent illness including, but not limited&#xD;
             to, ongoing or active infection, symptomatic congestive heart failure, unstable angina&#xD;
             pectoris, cardiac arrhythmia, any clinically active malabsorption syndrome,&#xD;
             inflammatory bowel disease, any condition that increases the risk of severe irinotecan&#xD;
             gastrointestinal toxicity, or psychiatric illness/social situations that would limit&#xD;
             compliance with study requirements&#xD;
&#xD;
          -  Patient must not be pregnant and/or breastfeeding&#xD;
&#xD;
          -  Patient must not be known to be human immunodeficiency virus (HIV)-positive on&#xD;
             combination antiretroviral therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Wang-Gillam, M.D., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>July 29, 2011</study_first_submitted>
  <study_first_submitted_qc>August 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2011</study_first_posted>
  <last_update_submitted>September 15, 2016</last_update_submitted>
  <last_update_submitted_qc>September 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

